X

Trial Profile

A Phase 2A, Randomized, Double-Blind, Placebo- Controlled, Multi-Center Study of Intravenous FDY-5301 in Acute Myocardial Infarction

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Feb 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs FDY 5301 (Primary)
Indications Myocardial infarction
Focus Therapeutic Use
Acronyms CAMPFIRE; IOCYTE-AMI Study
Sponsors Faraday Pharmaceuticals

Most Recent Events

15 Jan 2022 Results published in the International Journal of Cardiology
27 Dec 2021 According to a Faraday Pharmaceuticals media release, data from this trial will be published in the January 15, 2022 issue of the International Journal of Cardiology
27 Dec 2021 Results published in Faraday Pharmaceuticals Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com